Lateral Flow Assay Performance Verification: From Design Inputs to Analytical Claims

Lateral flow assays are designed to be quick, practical and easy to use. Achieving that simplicity requires a structured development process in which assay performance is defined, tested and understood in a systematic way. Performance depends on how well the assay design, materials, sample handling, readout and operating conditions have been understood during development and how clearly that understanding is turned into formal evidence.

As an assay moves towards technical transfer, regulatory submission or launch, the focus changes. It is no longer enough to know that the test works during development. The more important question is whether performance has been verified in a structured way that supports the final claims.

Performance verification is where that happens. It provides the planned studies and objective evidence needed to show how the assay performs, under which conditions it performs acceptably, how consistently it behaves and where its practical limits sit. For lateral flow assays, this is the stage at which development knowledge is converted into a claim supporting evidence package through predefined acceptance criteria, controlled studies and traceable reporting.

Within an IVD programme, this analytical work sits within the wider performance evaluation framework alongside scientific validity and clinical performance. Under IVDR, analytical performance needs to connect clearly to intended use, product requirements and the claims made for the assay. In practice, well planned performance verification supports more than technical understanding alone. It also helps create a clearer path towards transfer, submission and product readiness.

What is Performance Verification?

Performance verification is the formal process of demonstrating, through planned studies and predefined acceptance criteria, that a developed assay meets its specified requirements. In this context, verification is primarily concerned with confirming that the assay meets the technical specifications defined in the design inputs. In IVDR terms, this analytical work contributes to the broader performance evaluation evidence package.

Within a lateral flow assay programme, this stage typically follows feasibility and optimisation work and is carried out once the assay design has been frozen. At that point, performance verification uses formal protocols and controlled laboratory studies to generate objective, documented evidence that the design achieves its defined analytical performance characteristics. Depending on the assay, this may include detection capability, specificity, precision, measuring range, cut-off behaviour, stability, cross reactivity and interference.

Verification confirms that the final design configuration meets its technical specifications under controlled conditions. Validation, by contrast, addresses whether the device is fit for its intended use under conditions representative of use. This may include aspects of user interaction and operating context that controlled laboratory testing cannot fully replicate and, where applicable, clinical performance evidence appropriate to the intended use and claims.

Taken together, these studies provide the formal evidence base required for the design history file and for subsequent transfer and regulatory activities.

From Intended Use to Design Inputs

A robust performance verification programme starts before any protocol is written. It starts with the intended use or, in IVDR terms, the device’s intended purpose. Who is the test for? What sample type will be used? In what setting will it be used? What decision is it intended to support? What practical constraints matter, whether that is assay time, storage, sample handling, readability or ease of interpretation?

These questions define the user requirements for the product. They then need to be translated into design inputs that can guide assay development in a concrete way. For a lateral flow assay, those inputs often include required analytical sensitivity, acceptable specificity, supported matrices, cut-off or decision threshold, readout format, shelf life, acceptable variability and the handling conditions the device must tolerate.

This translation step is important because the intended use should determine which aspects of performance matter most and therefore which need to be challenged during formal verification. Expected clinical marker or antigen levels may help define the relevant working range or decision thresholds. Detection level requirements help set expectations for analytical sensitivity. The selected sample matrix helps determine which endogenous substances, sample characteristics or collection related factors may need to be assessed as potential interferents. The way the target is presented and its similarity to related analytes or organisms, can also shape the specificity requirements and identify areas where cross reactivity may need to be examined.

These inputs provide the basis for assay development and, later, for the verification studies used to demonstrate that the design meets its defined requirements.

From Development Studies to Formal Performance Verification

Formal performance verification begins once the assay design has been frozen and the relevant design inputs and acceptance criteria have been defined. At this stage, the work is no longer exploratory. Studies are planned in advance, executed under formal protocols and assessed against predefined acceptance criteria.

For lateral flow assays, this means that sample plans, replicate structures, challenge conditions and statistical methods are considered up front. The resulting evidence is captured in a structured form, including analysed data, statistical summaries and formal study reports, to support review by internal teams, external partners and regulators. Study designs should be built to address all relevant requirements, with study depth and challenge conditions shaped by the analytical risks and claim critical aspects of the assay. Depending on the format and intended use, this may include focused assessment of the cut-off region, low positive samples, likely interferents, cross reactivity, matrix dependent effects, lot related variability or operating conditions that could influence performance.

Using representative matrices and samples is an important part of this. Whole blood does not behave like serum and swab extracts, saliva, urine & environmental samples each bring their own flow characteristics, background effects and interference risks. Buffer based or heavily simplified contrived samples may be useful in earlier development, but they are not always sufficient for formal verification where matrix dependent effects are relevant to the claimed performance. Verification data is more meaningful when the study design reflects the intended sample matrix and the conditions under which the assay is expected to perform.

How Assay Format Shapes Study Strategy

The overall logic of performance verification remains consistent across lateral flow assay types, but the study strategy should be aligned to the type of result the assay is intended to deliver.

Qualitative assays provide a categorical result, typically reported as positive or negative based on a defined decision threshold. For these assays, the emphasis is on result classification, particularly around the decision region where the reliability of positive and negative calls needs to be demonstrated.

Semi-quantitative assays also provide categorical results, but these correspond to defined ranges or bands of analyte concentration rather than a simple positive or negative outcome. In this case, the focus shifts towards category boundaries, where relatively small changes in signal may alter band assignment and therefore the reported result.

Quantitative assays provide a numerical result that is intended to reflect the amount of analyte present in the sample. For these assays, the verification package is typically broader and places greater weight on characteristics such as detection capability, precision, bias, measuring range and linearity, because the claim depends on the reliability of a continuous measurement.

In each case, the core verification principles are the same, but the evidence package needs to be matched to the format and strength of the claim.

Core Analytical Performance Attributes

Reliable lateral flow assay performance is defined through a set of core analytical performance attributes linked to the technical specifications established in the design inputs. These studies provide the formal evidence needed to show that the design frozen assay meets those specifications, rather than relying on development stage observations alone.

Depending on the assay format and claim, relevant attributes may include detection capability, precision, analytical specificity, cross reactivity, interference and measuring range. CLSI guidance is particularly useful here because it offers structured approaches for study design, execution and data analysis.

Analytical Sensitivity (CLSI EP17)

Analytical sensitivity describes the assay’s ability to detect low concentrations of the target analyte and is often one of the key characteristics verified for a lateral flow assay. Where low end detection is central to the intended claim, this attribute becomes especially important because it helps define whether the assay can reliably distinguish true low level signal from background.

The main measures usually considered are the Limit of Blank (LoB), the Limit of Detection (LoD) and, where quantitation is relevant, the Limit of Quantitation (LoQ).

• LoB describes the highest apparent result expected when no analyte is present.

• LoD describes the lowest concentration that can be reliably distinguished from that background.

• LoQ describes the lowest concentration at which the analyte can be quantified with acceptable performance.

For lateral flow assays, these studies are most meaningful when performed in a matrix that reflects the intended sample type, particularly where background signal, non-specific binding or flow behaviour may affect performance near the claimed detection limit. 

Analytical Specificity: Interference and Cross Reactivity (CLSI EP07, EP12)

Analytical specificity addresses whether the assay responds to the intended target rather than to other substances. Interference studies examine whether endogenous or exogenous substances can distort the result, for example by creating false signal, suppressing a genuine response or altering interpretation near the decision threshold.

For lateral flow assays, this often involves testing potential cross reactants and interferents both in the absence of analyte and in the presence of analyte. Low positive samples are often particularly informative because suppression effects may be most significant close to the claimed detection limit or cut-off.

Matrix selection also matters. Whole blood, serum, plasma, saliva and other sample types can each interact differently with the assay system and additives such as anticoagulants or preservatives may also influence performance.

Precision: Repeatability and Reproducibility (CLSI EP05, EP12)

Precision describes the consistency of assay results when testing is repeated under defined conditions.

Repeatability refers to variation under closely matched conditions, such as the same operator, same run, same equipment and same lot where relevant. Reproducibility captures variation across broader sources of change, such as different operators, days, runs, instruments or lots.

For quantitative assays, these studies assess the consistency of numerical results under repeat and varied conditions. For qualitative and semi-quantitative lateral flow assays, the same principles apply, but the practical question is whether variation affects result classification, particularly near the decision threshold or category boundary. Study design therefore needs to reflect both the assay format and the type of claim being supported.

Linearity and Measuring Range (CLSI EP06)

For assays intended to support a numerical or graded result, linearity and measuring range are important parts of performance verification. The measuring range is the span of analyte concentrations over which the assay can meet its predefined performance criteria, while linearity examines whether assay response remains appropriately proportional to analyte concentration across the claimed interval.

For quantitative lateral flow assays, especially those using readers, these studies help define where the reportable range begins and ends and where the relationship between signal & concentration starts to depart from the expected behaviour. For semi-quantitative assays, dose response characterisation may also be useful where category assignment depends on graded signal behaviour.

Documentation Expectations for Performance Verification

Performance verification is only as useful as the documentation that supports it. The evidence needs to be traceable, reviewable and clearly linked back to predefined requirements, acceptance criteria and the design inputs the studies were intended to verify.

In practice, that means documenting study objectives, protocols, sample definitions, execution records, raw data, analysed outputs, deviations, statistical analyses and final interpretation in a controlled and coherent way. For submission, technical file review, manufacturing transfer or later design review, the quality of the documentation often determines how usable the evidence really is.

A practical documentation framework typically includes:

• Performance Verification Plan (PVP) - Defines the scope of verification, the performance attributes to be assessed, the acceptance criteria, the assay configuration to be tested and the overall study strategy.

  
  

• Protocols - Set out the detailed execution plan for each study, including sample handling, replicate structure, readout method, predefined analysis methods and how deviations will be recorded and assessed.

  
  

• Execution records and raw data - Capture what was done, by whom, using which materials, under which conditions and with what result, so that the study can be reconstructed and independently reviewed.

  
  

• Statistical analysis reports - Document how attributes such as LoD, precision, interference or linearity were evaluated, how the data were analysed and why the chosen approach was appropriate.

  
  

• Verification reports - Present the study results against the predefined acceptance criteria, assess whether requirements were met and explain any deviations, unexpected findings, limitations or claim impacts.

  
  

• Analytical performance summary - Brings the evidence together in a concise narrative linked back to intended use, product requirements, risk management and the final analytical claims.

  
  

Where this framework is strong, the evidence is easier to interpret, easier to defend and easier to integrate into the design history file and later technical documentation. Weak documentation, by contrast, can create gaps that only become visible during transfer, regulatory review or downstream validation work.

Why a CRO Can Add Real Value

At the performance verification stage, the most useful contribution from a CRO is not simply additional laboratory capacity. It is the ability to help shape the study strategy early, align verification work to the technical specifications defined in the design inputs, build practical & interpretable protocols and structure the resulting data into a package that supports submission. 

Early involvement allows a CRO to understand the assay design, intended use, design inputs and proposed claims while development is still progressing. That creates the opportunity to build performance verification plans, study designs and timelines in parallel, rather than trying to assemble them late in the programme. By the time the assay reaches design freeze, the verification strategy, protocol structure and documentation framework should already be in place and ready for execution.

That improves efficiency, but more importantly it reduces the risk of gaps in the evidence package. It also helps ensure that protocols reflect the assay itself rather than a generic template, that studies are sequenced appropriately and that the data generated is interpretable & directly linked back to the specifications they are intended to verify. This is particularly important because informal or poorly sequenced verification work can create documentation weaknesses that only become visible later during transfer, regulatory review or downstream validation activity.

A CRO can also add value by anticipating the practical constraints that shape verification work, including sample availability, matrix selection, lot strategy, comparator planning, where relevant, and the timing implications of longer running studies. Where this is done well, performance verification becomes more than a collection of individual experiments. It becomes a structured programme that produces evidence in a form that is technically defensible and usable in the next stage of development.

Conclusion

Performance verification is the stage at which a lateral flow assay moves from development understanding to formal analytical evidence. Once the design has been frozen and the relevant requirements have been defined, verification provides the structured studies needed to show that the assay meets its technical specifications under controlled conditions.

Its value lies in more than confirming that the assay can generate the expected result. A well planned verification programme shows how the assay performs, how consistently it behaves, where its practical limits sit and whether the final evidence is strong enough to support the intended claims. When this work is linked clearly to intended use, design inputs and predefined acceptance criteria, it creates a more reliable foundation for transfer, technical documentation and regulatory review.

For developers, this makes performance verification one of the most important points in the programme. It is where development knowledge is turned into a structured, traceable and defensible evidence package that supports the assay not just technically, but as a product.

Learn more about Fleet’s Lateral Flow Assay Development and Assay Performance Verification Services. Contact us to discuss your project and performance verification requirements.

Get in Touch